Myeloma research on the move.
作者信息
Ludwig Heinz
机构信息
Wilhelminen Cancer Research Institute, First Department of Medicine, Clinic Ottakring, Vienna, Austria.
出版信息
Blood Cancer J. 2021 Sep 17;11(9):155. doi: 10.1038/s41408-021-00550-z.
Abstract
摘要
相似文献
1
Myeloma research on the move.
Blood Cancer J. 2021 Sep 17;11(9):155. doi: 10.1038/s41408-021-00550-z.
2
Multiple myeloma.
Br J Hosp Med (Lond). 2017 Feb 2;78(2):C21-C27. doi: 10.12968/hmed.2017.78.2.C21.
3
Multiple myeloma in 2020: state of the art.
Panminerva Med. 2020 Dec;62(4):191-192. doi: 10.23736/S0031-0808.20.04159-2. Epub 2020 Sep 22.
4
Multiple myeloma: Updated approach to management in 2018.
Aust J Gen Pract. 2018 Aug;47(8):526-529. doi: 10.31128/AJGP-01-18-4473.
5
[The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):341-346. doi: 10.3760/cma.j.cn112138-20200304-00179.
6
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Eur J Haematol. 2021 Oct;107(4):416-427. doi: 10.1111/ejh.13678. Epub 2021 Jun 27.
7
Maintenance treatment in multiple myeloma.
Ann Oncol. 2008 Jun;19 Suppl 4:iv54-5. doi: 10.1093/annonc/mdn197.
8
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.
9
Diagnosis and therapy of multiple myeloma.
Korean J Intern Med. 2013 May;28(3):263-73. doi: 10.3904/kjim.2013.28.3.263. Epub 2013 May 1.
10
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22.
引用本文的文献
1
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Target Oncol. 2022 Jul;17(4):383-405. doi: 10.1007/s11523-022-00897-8. Epub 2022 Jun 30.
2
mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma.
Cancers (Basel). 2022 Jun 2;14(11):2766. doi: 10.3390/cancers14112766.
本文引用的文献
1
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
2
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
Nat Commun. 2021 Mar 25;12(1):1861. doi: 10.1038/s41467-021-22140-0.
3
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
4
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
Blood Cancer J. 2021 Feb 1;11(2):24. doi: 10.1038/s41408-021-00408-4.
5
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
6
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Oncotarget. 2020 Nov 10;11(45):4076-4081. doi: 10.18632/oncotarget.27792.
7
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29.
8
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Blood Cancer J. 2020 Oct 23;10(10):106. doi: 10.1038/s41408-020-00369-0.
9
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
10
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
Zotero 插件